See more : The Liberty Braves Group (BATRA) Income Statement Analysis – Financial Results
Complete financial analysis of Oscotec Inc. (039200.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oscotec Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Hokuhoku Financial Group, Inc. (8377.T) Income Statement Analysis – Financial Results
- KOSÉ Corporation (KSRYY) Income Statement Analysis – Financial Results
- STC Concrete Product Public Company Limited (STC.BK) Income Statement Analysis – Financial Results
- Automotive Axles Limited (AUTOAXLES.BO) Income Statement Analysis – Financial Results
- Shenzhen Laibao Hi-Tech Co., Ltd. (002106.SZ) Income Statement Analysis – Financial Results
Oscotec Inc. (039200.KQ)
About Oscotec Inc.
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.95B | 5.06B | 3.90B | 43.47B | 4.37B | 18.70B | 3.91B | 3.55B | 18.34B | 17.11B | 21.86B | 24.76B |
| Cost of Revenue | 2.03B | 3.49B | 3.29B | 2.88B | 2.68B | 2.71B | 1.96B | 1.80B | 10.25B | 9.61B | 12.59B | 16.71B |
| Gross Profit | 2.92B | 1.57B | 611.87M | 40.59B | 1.68B | 15.99B | 1.95B | 1.76B | 8.09B | 7.50B | 9.27B | 8.04B |
| Gross Profit Ratio | 58.99% | 31.04% | 15.68% | 93.38% | 38.57% | 85.51% | 49.86% | 49.43% | 44.12% | 43.86% | 42.39% | 32.49% |
| Research & Development | 24.91B | 23.34B | 22.65B | 35.46B | 15.41B | 6.97B | 4.82B | 1.57B | 2.00B | 2.14B | 2.37B | 1.96B |
| General & Administrative | 2.18B | 1.64B | 1.18B | 1.26B | 589.73M | 289.97M | 263.80M | 68.72M | 146.70M | 143.92M | 176.08M | 245.97M |
| Selling & Marketing | 1.68B | 1.15B | 1.06B | 1.02B | 1.04B | 651.85M | 643.87M | 431.66M | 1.07B | 1.33B | 1.39B | 2.04B |
| SG&A | 8.64B | 6.42B | 5.72B | 5.87B | 8.00B | 2.77B | 2.85B | 1.86B | 5.17B | 5.51B | 7.12B | 6.22B |
| Other Expenses | 0.00 | -324.95M | -251.45M | -373.93M | -196.12M | -79.26M | -79.45M | -61.05M | -236.90M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.58B | 30.09B | 28.62B | 41.71B | 23.61B | 9.82B | 7.75B | 3.50B | 7.41B | 9.20B | 12.68B | 16.49B |
| Cost & Expenses | 37.61B | 33.58B | 31.92B | 44.58B | 26.29B | 12.53B | 9.71B | 5.29B | 17.66B | 18.81B | 25.27B | 33.20B |
| Interest Income | 4.76B | 1.22B | 230.33M | 702.18M | 688.60M | 774.32M | 475.78M | 615.86M | 600.03M | 412.70M | 414.44M | 721.68M |
| Interest Expense | 406.64M | 316.40M | 107.65M | 709.24M | 1.21B | 1.27B | 484.58M | 692.89M | 669.93M | 531.50M | 620.00M | 957.02M |
| Depreciation & Amortization | 1.86B | 1.64B | 1.46B | 1.07B | 620.61M | 307.94M | 317.28M | 338.91M | 513.79M | 411.98M | 409.61M | 2.90B |
| EBITDA | -30.02B | -26.03B | -27.02B | 2.64B | -20.82B | 6.78B | -5.57B | -6.26B | 1.19B | -1.10B | -2.80B | -5.37B |
| EBITDA Ratio | -606.35% | -530.89% | -680.36% | -0.10% | -487.69% | 34.68% | -140.42% | -39.41% | 6.51% | -2.01% | -2.18% | 8.52% |
| Operating Income | -30.63B | -28.52B | -28.01B | -1.11B | -21.93B | 6.18B | -5.81B | -1.74B | 680.60M | -756.27M | -885.16M | -792.85M |
| Operating Income Ratio | -618.65% | -563.29% | -717.76% | -2.56% | -501.89% | 33.03% | -148.54% | -48.95% | 3.71% | -4.42% | -4.05% | -3.20% |
| Total Other Income/Expenses | -1.65B | -1.26B | -570.55M | -287.20M | -1.51B | -978.34M | -574.40M | -3.47B | -378.21M | -1.35B | -2.94B | -8.39B |
| Income Before Tax | -32.28B | -27.98B | -28.58B | 1.29B | -22.65B | 5.20B | -6.38B | -4.91B | 302.39M | -2.11B | -3.83B | -9.17B |
| Income Before Tax Ratio | -652.07% | -552.76% | -732.38% | 2.97% | -518.58% | 27.80% | -163.23% | -138.04% | 1.65% | -12.33% | -17.51% | -37.03% |
| Income Tax Expense | -3.79B | -209.32M | 6.93M | 3.34B | 2.31B | 920.97M | -523.40M | -36.82M | -61.04M | 53.59M | 110.30M | 5.22B |
| Net Income | -24.28B | -24.43B | -26.26B | -4.36B | -22.44B | 3.47B | -5.86B | -3.65B | 395.03M | -2.02B | -3.97B | -14.48B |
| Net Income Ratio | -490.40% | -482.57% | -672.93% | -10.02% | -513.57% | 18.56% | -149.84% | -102.58% | 2.15% | -11.82% | -18.17% | -58.48% |
| EPS | -635.00 | -763.19 | -827.37 | -142.54 | -759.66 | 121.64 | -211.09 | -137.32 | 15.85 | -90.37 | -182.53 | -811.00 |
| EPS Diluted | -634.86 | -763.19 | -827.37 | -142.54 | -759.66 | 121.64 | -211.09 | -137.32 | 15.45 | -90.37 | -182.53 | -811.00 |
| Weighted Avg Shares Out | 38.24M | 32.01M | 31.74M | 30.56M | 29.53M | 28.53M | 27.74M | 26.55M | 24.92M | 22.38M | 21.75M | 17.85M |
| Weighted Avg Shares Out (Dil) | 38.24M | 32.01M | 31.74M | 30.56M | 29.53M | 28.53M | 27.74M | 26.55M | 25.57M | 22.38M | 21.75M | 17.85M |
Source: https://incomestatements.info
Category: Stock Reports